Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura
The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.
ASH 2017
Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism
Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.
Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies
Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.
Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia
Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.
High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML
Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.
Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL
Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.
Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3-mutated AML
At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.
Dasatinib Is Safe and Effective in Philadelphia Chromosome-positive Pediatric ALL
Researchers assessed the efficacy of dasatinib — a TKI that is significantly more potent than imatinib and is active even in the setting of imatinib resistance — in this patient population.
Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia
Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.
Daratumumab Plus Standard Care Doubles PFS in Newly Diagnosed Multiple Myeloma
A previous study demonstrated that patients with relapsed MM have a superior PFS and greater depth of response when treated with D-VMP.
Want to read more?
Please login or register first to view this content.
Next post in ASH 2017
